Targeting cancer using kat inhibitors to mimic lethal knockouts
Brown, J. A. L. ; Bourke, E. ; Eriksson, L. A. ; Kerin, M. J.
Brown, J. A. L.
Bourke, E.
Eriksson, L. A.
Kerin, M. J.
Repository DOI
Publication Date
2016-08-15
Type
Article
Downloads
Citation
Brown, J. A. L. Bourke, E.; Eriksson, L. A.; Kerin, M. J. (2016). Targeting cancer using kat inhibitors to mimic lethal knockouts. Biochemical Society Transactions 44 , 979-986
Abstract
Two opposing enzyme classes regulate fundamental elements of genome maintenance, gene regulation and metabolism, either through addition of an acetyl moiety by histone acetyltransferases (HATs) or its removal by histone de-acetyltransferases (HDAC), and are exciting targets for drug development. Importantly, dysfunctional acetylation has been implicated in numerous diseases, including cancer. Within the HAT superfamily theMYST family holds particular interest, as its members are directly involved in the DNA damage response and repair pathways and crucially, several members have been shown to be down-regulated in common cancers (such as breast and prostate). In the present study we focus on the development of lysine (K) acetyltransferase inhibitors (KATi) targeting the MYST family member Tip60 (Kat5), an essential protein, designed or discovered through screening libraries. Importantly, Tip60 has been demonstrated to be significantly down-regulated in many cancers which urgently require new treatment options. We highlight current and future efforts employing these KATi as cancer treatments and their ability to synergize and enhance current cancer treatments. We investigate the different methods of KATi production or discovery, their mechanisms and their validation models. Importantly, the utility of KATi is based on a key concept: using KATi to abrogate the activity of an already down-regulated essential protein (effectively creating a lethal knockout) provides another innovative mechanism for targeting cancer cells, while significantly minimizing any off-target effects to normal cells. This approach, combined with the rapidly developing interest in KATi, suggests that KATi have a bright future for providing truly personalized therapies.
Funder
Publisher
Portland Press Ltd.
Publisher DOI
10.1042/bst20160081
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland